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PERSPECTIVE
Why Do Cyclo-Oxygenase-2
Inhibitors Cause Cardiovascular Events?
Richard J. Bing, MD, Magdalena Lomnicka
Pasadena, California
This report confirms evidence that selective nonsteroidal anti-inflammatory drugs (NSAIDs),
such as celecoxib, can lead to thrombotic cardiovascular events. Aspirin, a nonselective
COX-1 (cyclo-oxygenase) and COX-2 inhibitor may result in gastric toxicity. For this reason,
selective COX-2 inhibitors have been developed to reduce erosion of the gastric mucosa. Both
selective and nonselective NSAIDs reduce prostacyclin formation in the infarcted heart; they
accomplish this by tipping the balance of prostacyclin/thromboxane in favor of thromboxane,
a prothrombotic eicosanoid. The relative increase in thromboxane, coupled with a diminution
in prostacyclin in infarcted heart muscle, can lead to the development of thrombotic
cardiovascular events. This may be prevented by the addition of a nitric oxide donor to
NSAIDs. (J Am Coll Cardiol 2002;39:521–2) © 2002 by the American College of
Cardiology
Cyclo-oxygenase (COX) or prostaglandin endoperoxidase
H synthase inhibitors are important contributors to the
treatment of arthritis and other inflammatory conditions.
Cyclo-oxygenases catalyze the conversion of arachidonic
acid and O2 to PGH2, the committed step in prostanoid
synthesis (1). The two isoenzymes, COX-1 and COX-2, are
encoded by separate genes located on different chromo-
somes. The COX-2 expression can be induced through
multiple signaling pathways involving protein kinases A and
C, tyrosine kinases and bacterial endotoxin, among others
(1). Both isoenzymes are homodimeric, heme-containing
glycosylated proteins with two catalytic sites (1). They are
targets of nonselective nonsteroidal anti-inflammatory drugs
(NSAIDs); aspirin, a nonselective NSAID, acts via COX-1
to inhibit platelet thromboxane A2 formation and, there-
fore, lowers mortality from ischemic heart disease (1).
Inhibition of COX-2 reduces inflammation, fever and
probably colon cancer (2,3). Covalent modifications of
COX enzymes by aspirin cause permanent inactivation of
the enzyme (1). Because of their anti-inflammatory action,
COX inhibitors have been selected for long-term treatment
of inflammatory conditions. The COX-2 inhibitors predis-
pose to erosion of the gastric mucosa with subsequent
hemorrhage. Both COX-2 selective and nonselective COX
inhibitors cause renal toxicity with papillary necrosis and
interstitial nephritis (4).
Recently, Mukherjee et al. (5) analyzed clinical trials
dealing with the effect of celecoxib and rofecoxib, two
selective COX-2 inhibitors, on cardiovascular events. They
concluded that these two inhibitors are responsible for a
significant risk of cardiovascular thrombotic events. Based
on one of the clinical trials (Vioxx Gastrointestinal Out-
comes Research), they showed that the relative risk of
developing thrombotic cardiovascular events such as myo-
cardial infarction or unstable angina was high as compared
to naproxen, a nonselective COX inhibitor (5). The inves-
tigators conclude that COX-2 inhibition favors prothrom-
botic events by tipping the balance of prostacyclin/
thromboxane in favor of thromboxane, a prethrombotic
eicosanoid (5). Experimental data have confirmed these
conclusions.
The release of prostaglandins from ischemic tissue was
first demonstrated by McGiff et al. (6). The heart metabo-
lizes arachidonic acid into different prostaglandins (7),
particularly prostacyclin (8). An increase in prostaglandins
in canine coronary venous blood occurs during postocclusive
reactive hyperemia (9). Acute myocardial ischemia not only
increases prostacyclin but also thromboxane in coronary vein
blood (10). Prostacyclin increases in microsomes prepared
from infarcted myocardium (10). It is likely that macro-
phages are the main source of prostaglandins and throm-
boxane (11). Production of prostacyclin and thromboxane
by the infarcted heart in situ occurs in conjunction with
increased activation of the inducible form of nitric oxide-
synthase (iNOS) (12). The induction of iNOS in the
ischemic rabbit and human heart increases the coronary
arterial-venous coronary difference of NO2 and NO3 (NOx).
Activation of iNOS occurs primarily by activated macro-
phages during the inflammatory phase (12).
Both nitric oxide (NO) and prostaglandins play an
important role in the infarcted heart (2). Prostacyclin is a
vasodilator that prevents cardiac arrhythmias and platelet
aggregation; thromboxane, in contrast, promotes platelet
aggregation, acts as a vasoconstrictor and initiates ventric-
ular arrhythmias (2). Nitric oxide counteracts thromboxane,
inhibits platelet aggregation and compensates for the
NSAIDs’ induced reduction of prostacyclin (2). Production
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of thromboxane and prostacyclin in the infarcted rabbit
heart has been confirmed together with increased upgrading
of iNOS (9). The interaction between COX and iNOS is
due to an iron-heme center as the active site of COX (9).
Exogenous NO, together with cytokine-induced NO, en-
hances both COX isoenzymes (9). Upgrading of COX-2
protein by cytokines is also accomplished by NSAIDs. This
action differs from upgrading by inflammatory cytokines,
which increase COX at the transcriptional levels (13).
Recently, we obtained evidence of changes in the pros-
tacyclin/thromboxane ratio after celecoxib, which lowers
myocardial prostacyclin production in infarcted heart mus-
cle, but fails to inhibit thromboxane (14). Therefore, cele-
coxib (5 mg/kg) tips the balance of prostacyclin/
thromboxane in favor of thromboxane, leading to increased
vascular and thrombotic events (14). In contrast, the non-
selective COX inhibitor aspirin (35 mg/kg/d) suppresses
both prostacyclin and thromboxane (15).
Both NO and prostacyclin counteract the effect of throm-
boxane on platelet aggregation and, therefore, on throm-
botic events (2,16). Nitric oxide is particularly important in
the presence of diminished prostacyclin or unchanged and
increased thromboxane. Celecoxib does not inhibit induc-
tion of iNOS, but decreases the ratio of prostacyclin/
thromboxane (14). Prostacyclin and NO have an additional
and different impact on the infarcted heart and tumor
progression. For example, prostacyclin increases the poten-
tial for stimulating growth of new blood vessels in cancer
and the infarcted heart muscle. Angiogenesis in tumors is
undesirable because it may promote the spread of the tumor;
it plays an important positive role in healing and remodeling
of the infarcted heart (3).
How can one avoid these thrombotic events following
NSAIDs? One possibility is to supplement COX-2 inhib-
itors with small doses of aspirin, as suggested by Mukherjee
et al. (5). Another possibility is the combination of the
COX-2 inhibitors with a NO donor, B-NOD; this is a
newly developed NO donor that can be administered orally,
its effect persisting for more than 7 h, causing no drop in
blood pressure nor an increase in heart rate; it increases
cyclic guanosine monophosphate and prevents platelet ag-
gregation. In vitro, release of NO by B-NOD is augmented
by the presence of blood platelets (17). We had previously
suggested that a combination of aspirin with a NO donor may
prevent the decline of prostacyclin after aspirin alone and
celecoxib (8,13). The relative proportion of each component
would have to be determined. A combination of NSAIDs and
B-NOD has already been used to prevent renal depletion of
prostacyclin in situ following administration of aspirin (18).
It is realized that re-evaluation of a commercially success-
ful compound is not a desirable course. Conversely, science
should not be hampered by a matter of expediency. Progress
depends on re-evaluation of known facts; there are no
immovable objects in either science or medicine.
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Abbreviations and Acronyms
COX  cyclo-oxygenase
iNOS  inducible form of nitric oxide-synthase
NO  nitric oxide
NSAID  nonsteroidal anti-inflammatory drug
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